Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-04-14

Clinical Trial Update: Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of avelumab in small intestinal adenocarcinoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avelumab (avelumab)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-04-14